JP2017518348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518348A5 JP2017518348A5 JP2016574004A JP2016574004A JP2017518348A5 JP 2017518348 A5 JP2017518348 A5 JP 2017518348A5 JP 2016574004 A JP2016574004 A JP 2016574004A JP 2016574004 A JP2016574004 A JP 2016574004A JP 2017518348 A5 JP2017518348 A5 JP 2017518348A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- optionally substituted
- disorder
- cancer
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 22
- 230000001684 chronic effect Effects 0.000 claims description 18
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 16
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 14
- -1 Benzotriazinyl Chemical group 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 125000003107 substituted aryl group Chemical group 0.000 claims description 13
- 206010020751 Hypersensitivity Diseases 0.000 claims description 12
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 12
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 208000026935 allergic disease Diseases 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 208000020084 Bone disease Diseases 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 8
- 108090000190 Thrombin Proteins 0.000 claims description 8
- 230000030833 cell death Effects 0.000 claims description 8
- 230000001066 destructive effect Effects 0.000 claims description 8
- 208000016361 genetic disease Diseases 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 8
- 229960004072 thrombin Drugs 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 230000007170 pathology Effects 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 6
- 208000015943 Coeliac disease Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims description 6
- 101150053046 MYD88 gene Proteins 0.000 claims description 6
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 206010047115 Vasculitis Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 6
- 201000009890 sinusitis Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 5
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 5
- 201000002481 Myositis Diseases 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 5
- 201000008383 nephritis Diseases 0.000 claims description 5
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 201000011152 Pemphigus Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 3
- 206010001889 Alveolitis Diseases 0.000 claims description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 206010003011 Appendicitis Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000023611 Burkitt leukaemia Diseases 0.000 claims description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 241001317099 Dystaxia Species 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- 201000011275 Epicondylitis Diseases 0.000 claims description 3
- 206010016228 Fasciitis Diseases 0.000 claims description 3
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 3
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000022461 Glomerular disease Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000003807 Graves Disease Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
- 206010023347 Keratoacanthoma Diseases 0.000 claims description 3
- 201000008197 Laryngitis Diseases 0.000 claims description 3
- 206010024238 Leptospirosis Diseases 0.000 claims description 3
- 208000004852 Lung Injury Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 206010028289 Muscle atrophy Diseases 0.000 claims description 3
- 208000003926 Myelitis Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
- 208000005141 Otitis Diseases 0.000 claims description 3
- 208000027868 Paget disease Diseases 0.000 claims description 3
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 208000007452 Plasmacytoma Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 206010036774 Proctitis Diseases 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 201000010208 Seminoma Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 3
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 208000000491 Tendinopathy Diseases 0.000 claims description 3
- 206010043255 Tendonitis Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010069351 acute lung injury Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000004631 alopecia areata Diseases 0.000 claims description 3
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 3
- 230000001925 catabolic effect Effects 0.000 claims description 3
- 206010008323 cervicitis Diseases 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 208000003167 cholangitis Diseases 0.000 claims description 3
- 201000001352 cholecystitis Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 claims description 3
- 208000007784 diverticulitis Diseases 0.000 claims description 3
- 208000019258 ear infection Diseases 0.000 claims description 3
- 210000003981 ectoderm Anatomy 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 206010014665 endocarditis Diseases 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 210000003979 eosinophil Anatomy 0.000 claims description 3
- 210000000918 epididymis Anatomy 0.000 claims description 3
- 201000010063 epididymitis Diseases 0.000 claims description 3
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 208000030941 fetal growth restriction Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 230000003325 follicular Effects 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 231100000852 glomerular disease Toxicity 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000007475 hemolytic anemia Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims description 3
- 210000004276 hyalin Anatomy 0.000 claims description 3
- 206010020718 hyperplasia Diseases 0.000 claims description 3
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 3
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims description 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 206010023332 keratitis Diseases 0.000 claims description 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000011486 lichen planus Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 231100000515 lung injury Toxicity 0.000 claims description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000004396 mastitis Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 claims description 3
- 208000009928 nephrosis Diseases 0.000 claims description 3
- 231100001027 nephrosis Toxicity 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 206010057056 paraneoplastic pemphigus Diseases 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 208000008494 pericarditis Diseases 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 206010034674 peritonitis Diseases 0.000 claims description 3
- 208000001297 phlebitis Diseases 0.000 claims description 3
- 208000008423 pleurisy Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 208000003265 stomatitis Diseases 0.000 claims description 3
- 201000004595 synovitis Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 201000004415 tendinitis Diseases 0.000 claims description 3
- 210000001550 testis Anatomy 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 3
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 208000004145 Endometritis Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010034038 Parotitis Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000003416 augmentation Effects 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 230000002062 proliferating effect Effects 0.000 claims 6
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 2
- 206010015218 Erythema multiforme Diseases 0.000 claims 2
- 206010037596 Pyelonephritis Diseases 0.000 claims 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 210000003905 vulva Anatomy 0.000 claims 2
- 206010005149 Blepharitis allergic Diseases 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 241000519995 Stachys sylvatica Species 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000018339 bone inflammation disease Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000000281 joint capsule Anatomy 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 210000004561 lacrimal apparatus Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 210000003681 parotid gland Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 0 C*(C(NNC(C)(C)*)=O)C1=CC2*=*=C(CC3=C=N3)C2C=C1* Chemical compound C*(C(NNC(C)(C)*)=O)C1=CC2*=*=C(CC3=C=N3)C2C=C1* 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3017CH2014 | 2014-06-20 | ||
| IN3017/CHE/2014 | 2014-06-20 | ||
| PCT/IB2015/054620 WO2015193846A1 (en) | 2014-06-20 | 2015-06-19 | Substituted indazole compounds as irak4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017518348A JP2017518348A (ja) | 2017-07-06 |
| JP2017518348A5 true JP2017518348A5 (enExample) | 2018-08-02 |
Family
ID=54934936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574004A Pending JP2017518348A (ja) | 2014-06-20 | 2015-06-19 | Ｉｒａｋ４阻害剤としての置換インダゾール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170152263A1 (enExample) |
| EP (1) | EP3157521A4 (enExample) |
| JP (1) | JP2017518348A (enExample) |
| KR (1) | KR20170016500A (enExample) |
| CN (1) | CN106456609A (enExample) |
| AU (1) | AU2015275730A1 (enExample) |
| BR (1) | BR112016029853A2 (enExample) |
| CA (1) | CA2952188A1 (enExample) |
| CU (1) | CU20160188A7 (enExample) |
| EA (1) | EA201692418A1 (enExample) |
| HK (1) | HK1231411A1 (enExample) |
| IL (1) | IL249345A0 (enExample) |
| MX (1) | MX2016017147A (enExample) |
| PH (1) | PH12016502382A1 (enExample) |
| SG (1) | SG11201610009XA (enExample) |
| WO (1) | WO2015193846A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181795T1 (hr) | 2014-01-13 | 2019-01-25 | Aurigene Discovery Technologies Limited | Biciklički heterociklilni derivati kao inhibitori irak4 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| EP3195865A1 (de) | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Kombinationen von irak4 inhibitoren und btk inhibitoren |
| CA2984259C (en) | 2015-04-30 | 2024-02-13 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| HK1249509A1 (zh) * | 2015-07-15 | 2018-11-02 | Aurigene Discovery Technologies Limited | 作为irak-4抑制剂的吲唑及氮杂吲唑化合物 |
| WO2017108723A2 (en) * | 2015-12-22 | 2017-06-29 | F. Hoffmann-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| US10435396B2 (en) | 2016-03-03 | 2019-10-08 | Bayer Pharma Aktiegesellschaft | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| WO2017207386A1 (de) * | 2016-06-01 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen |
| AU2017272505B9 (en) | 2016-06-01 | 2021-10-28 | Bayer Pharma Aktiengesellschaft | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
| MA46191A (fr) | 2016-09-09 | 2021-04-21 | Incyte Corp | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| CN109890829B (zh) | 2016-11-02 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| IL269536B (en) | 2017-03-31 | 2022-07-01 | Aurigene Discovery Tech Ltd | Compounds and preparations for the treatment of hematological disorders |
| WO2018234343A1 (en) * | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | BENZOFURANES AS MODULATORS OF IRAQ4 |
| EP3642204A1 (en) | 2017-06-21 | 2020-04-29 | H. Hoffnabb-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| WO2018234342A1 (en) | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4 |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス， インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
| PL3704108T3 (pl) | 2017-10-31 | 2024-07-22 | Curis, Inc. | Inhibitor irak4 w połączeniu z inhibitorem bcl-2 do stosowania w leczeniu nowotworu złośliwego |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11542251B2 (en) | 2018-02-14 | 2023-01-03 | Dana-Farber Cancer Institute, Inc. | IRAK degraders and uses thereof |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
| CN112236429B (zh) * | 2018-04-05 | 2024-10-11 | 默克专利有限公司 | 用作ii型irak抑制剂的杂芳基化合物及其用途 |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| CN110833559A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗急性肺损伤致肺纤维化的用途 |
| WO2020035019A1 (zh) | 2018-08-17 | 2020-02-20 | 浙江海正药业股份有限公司 | 吲唑胺类衍生物及其制备方法和其在医药上的用途 |
| WO2020048471A1 (zh) * | 2018-09-06 | 2020-03-12 | 浙江海正药业股份有限公司 | 7-取代吲唑类衍生物及其制备方法和其在医药上的用途 |
| JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物 |
| PH12021500026A1 (en) | 2018-11-30 | 2022-05-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN114127075B (zh) * | 2019-07-18 | 2024-05-14 | 百时美施贵宝公司 | 可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物 |
| CN114450276A (zh) | 2019-08-06 | 2022-05-06 | 因赛特公司 | Hpk1抑制剂的固体形式 |
| WO2021047677A1 (zh) * | 2019-09-12 | 2021-03-18 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| EP4076520A4 (en) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics, Inc. | IRAQ DEGRADATION AGENTS AND THEIR USES |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| AU2021320052A1 (en) * | 2020-08-04 | 2023-03-23 | Aurigene Oncology Limited | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders |
| CN116745294A (zh) * | 2020-12-25 | 2023-09-12 | 南京明德新药研发有限公司 | 酰胺噁唑类化合物 |
| KR20230143632A (ko) | 2020-12-30 | 2023-10-12 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| IL304907A (en) | 2021-02-15 | 2023-10-01 | Kymera Therapeutics Inc | Irak4 degraders and uses thereof |
| AU2022254933A1 (en) | 2021-04-08 | 2023-11-09 | Curis, Inc. | Combination therapies for the treatment of cancer |
| TW202309030A (zh) | 2021-05-07 | 2023-03-01 | 美商凱麥拉醫療公司 | Cdk2降解劑及其用途 |
| CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| TW202330546A (zh) * | 2021-12-31 | 2023-08-01 | 香港商愛科諾生物醫藥(香港)有限公司 | 具有irak4抑制活性的化合物，包含其的藥物組合物，及其應用 |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1181327A (en) * | 1915-08-10 | 1916-05-02 | Michael F Mcandrew | Basket construction and guard therefor. |
| US1301085A (en) * | 1916-11-06 | 1919-04-15 | Charles R Hadley Company | Loose-leaf binder. |
| JP2995086B2 (ja) * | 1990-05-18 | 1999-12-27 | ヘキスト・アクチエンゲゼルシヤフト | イソオキサゾール−４−カルボキサミド類およびヒドロキシアルキリデンシアノアセトアミド類を含有する製剤 |
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US20030134836A1 (en) * | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| DE10162375A1 (de) * | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
| US7151113B2 (en) * | 2003-05-01 | 2006-12-19 | Bristol Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
| EP1627869B1 (en) * | 2003-05-20 | 2012-05-02 | Ajinomoto Co., Inc. | Vanilloid receptor modulators |
| WO2004108133A2 (en) * | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| WO2005034870A2 (en) * | 2003-10-07 | 2005-04-21 | Renovis, Inc. | Amide compounds and ion channel ligands and uses thereof |
| CN102633783A (zh) * | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| NZ575410A (en) * | 2006-09-07 | 2012-03-30 | Biogen Idec Inc | 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives |
| JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CA2690619A1 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| NZ587039A (en) * | 2008-02-13 | 2013-01-25 | Gilead Connecticut Inc | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| EP2488486B1 (en) * | 2009-10-13 | 2019-08-14 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
| AU2011242711C1 (en) * | 2010-04-22 | 2016-04-21 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| CA2793697A1 (en) * | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Inhibitors of phosphoinositide dependent kinase 1 (pdk1) |
| JP2013529647A (ja) * | 2010-06-24 | 2013-07-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| JP6073343B2 (ja) * | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
| GB201119401D0 (en) * | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| MX2016009011A (es) * | 2014-01-10 | 2017-01-23 | Aurigene Discovery Tech Ltd | Compuestos de indazol como inhibidores de cinasa-4 asociada al receptor de interleucina-1 (irak4). |
| SG11201606367YA (en) * | 2014-02-06 | 2016-09-29 | Abbvie Inc | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
-
2015
- 2015-06-19 EA EA201692418A patent/EA201692418A1/ru unknown
- 2015-06-19 CU CUP2016000188A patent/CU20160188A7/es unknown
- 2015-06-19 CN CN201580033142.0A patent/CN106456609A/zh active Pending
- 2015-06-19 WO PCT/IB2015/054620 patent/WO2015193846A1/en not_active Ceased
- 2015-06-19 SG SG11201610009XA patent/SG11201610009XA/en unknown
- 2015-06-19 BR BR112016029853A patent/BR112016029853A2/pt not_active IP Right Cessation
- 2015-06-19 US US15/320,111 patent/US20170152263A1/en not_active Abandoned
- 2015-06-19 EP EP15809538.0A patent/EP3157521A4/en not_active Withdrawn
- 2015-06-19 JP JP2016574004A patent/JP2017518348A/ja active Pending
- 2015-06-19 CA CA2952188A patent/CA2952188A1/en not_active Abandoned
- 2015-06-19 HK HK17105243.5A patent/HK1231411A1/zh unknown
- 2015-06-19 MX MX2016017147A patent/MX2016017147A/es unknown
- 2015-06-19 AU AU2015275730A patent/AU2015275730A1/en not_active Abandoned
- 2015-06-19 KR KR1020177001487A patent/KR20170016500A/ko not_active Withdrawn
-
2016
- 2016-11-29 PH PH12016502382A patent/PH12016502382A1/en unknown
- 2016-12-01 IL IL249345A patent/IL249345A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518348A5 (enExample) | ||
| JP7500819B2 (ja) | Ｔａｍ阻害剤としてのピロロトリアジン化合物 | |
| JP2017505337A5 (enExample) | ||
| ES2927104T3 (es) | Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer | |
| JP2017502088A5 (enExample) | ||
| ES2975436T3 (es) | Enantiómeros (R) y (S) de n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4- il)oxazol-carboxamida como inhibidores de IRAK4 para el tratamiento del cáncer | |
| CN105263931B (zh) | 作为fgfr抑制剂的双环杂环 | |
| AU2012363558B2 (en) | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases | |
| BR112021007679A2 (pt) | inibidores de tyk2 e seus usos | |
| JP2022166179A (ja) | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス | |
| CA3015484A1 (en) | Novel condensed pyrimidine compound or salt thereof | |
| JP2023529108A (ja) | インダゾール誘導体ならびにその調製方法および応用 | |
| AU2016293441A1 (en) | Indazole and azaindazole compounds as IRAK-4 inhibitors | |
| CN110229142A (zh) | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 | |
| JP2016531870A5 (enExample) | ||
| PT2074120E (pt) | Compostos de tropano | |
| CN115557933B (zh) | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 | |
| JP2020525512A (ja) | 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物 | |
| AU2015402778B2 (en) | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| US11753418B2 (en) | Compounds for the modulation of Myc activity | |
| CA3019026A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| KR20200134179A (ko) | N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
| CA3240011A1 (en) | Fused thiazolopyrimidine derivatives as mnks inhibitors | |
| JP2019514951A (ja) | 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体 | |
| WO2025034951A1 (en) | Pharmaceutical compounds and compositions as c-kit kinase inhibitors |